PAK6

Across TCGA pan-cancer cohorts, PAK6 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PAK6 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PAK6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PAK6 expression acts as an unfavorable survival marker.

LUAD, ESCA, and PRAD are the cancer types where PAK6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.166	0.712	<.001	51	view →
ESCA	OS	Median	All	0.330	0.691	.005	9	view →
PRAD	DFS	Median	All	0.085	0.774	.007	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
BLCA	OS	Median	III,IV	0.187	0.684	.006	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PAK6–LUAD (OS)

Open the LUAD breakdown →